# Need & Solution Specification Framework

NB: this is an old thinking framework trying to distill a lot of things I'd learned into a more actionable biotech project evaluation map. Has not been updated since ~2019. May be updated for how incoming trends in ML, automation, and regulatory changes affect this.

- 1. Need Specification
    - a. Need Identity
        - i. Framework: Describe need @ 5 levels of understanding: grandma, undergrad in field, graduate student in field, professor near field, industry vet in field
        - ii. Need Components
            - 1. Clinical manifestations and differential diagnosis criteria
                - a. Symptoms and etiology
                    - i. Prodromes, heredity, and exposure risks
                    - ii. Symptoms that motivate patients to seek care
                    - iii. Disease progression characteristics
                    - iv. What we know about molecular-, cell-, organ- and tissue-level etiologies
                    - v. History of pathology
                        - 1. Common patient histories
                        - 2. History of medical model of understanding, detecting, and treating the condition
                - b. Patient populations affected
                    - i. Size, trends, locations, other characteristics
                    - ii. Heterogeneity of disease stage and symptoms @ diagnosis
                    - iii. Epidemiology
                - c. Differential diagnosis discriminatory criteria
                    - i. Inclusionary criteria and tests
                    - ii. Exclusionary criteria and tests
                    - iii. Common misdiagnoses
                    - iv. Is barbarian knowledge on diagnosis available from experienced doctors?
                    - v. Prognostic correlations
                - d. Setting / implementation of care
                - e. High-level trends and risks
                    - i. Risk factors in health
                    - ii. Policy
                    - iii. Economic
            - 2. Mechanisms
                - a. Molecular interactions – known + putative
                - b. Cellular populations involved
                    - i. Homeostatic function of each
                    - ii. Function in disease / pathology area for each
                    - iii. Response to inflammation for each
                    - iv. Known significant interactions
                    - v. How each would try to return to homeostasis
                - c. Tissues and organ systems affected
                - d. Patient heterogeneity
                    - i. GWAS, OMIM, and ClinVar results
                    - ii. Differences in disease presentation
                    - iii. Common co-morbidities
                    - iv. Environmental and lifestyle risks
                    - v. Disease state at the time of diagnosis
                    - vi. Side effect patterns by co-morbidity, polypharmacology, incidence in given backgrounds
                    - vii. Differences in response to current treatment
                    - viii. Access to care / clinical experience
                    - ix. Idiopathic forms of the disease
            - 3. Current treatments / solutions to need
                - a. Efficacy of current treatments
                    - i. Disease stabilization / progression / regression
                        - 1. Long-term efficacy
                        - 2. Long-term patient adherence
                    - ii. Side effect profiles
                    - iii. History of indications each treatment approved for
                    - iv. Interactions and effects in co-treatment
                    - v. Polypharmacology of treatment with emphasis on treatments used for co-morbidities
                    - vi. Criteria upon which previous / current solutions were granted market approval
                    - vii. Traditional medicine and supplements used for the condition
                - b. Mechanism of action of current treatments, including hypotheses when MOA has not been directly shown
                - c. IP ownership landscape
                    - i. Architecture of claims
                    - ii. Scope and nature of accepted inventive steps
                    - iii. Unprotected prior art
                    - iv. What "skilled in the art of" would mean for this particular field
                    - v. Patentability criteria of past, present, and emerging solutions if obtainable
                - d. Mfg capacity landscape
                    - i. cGMP requirements for the composition of matter
                    - ii. Identify any rare components / equipment needed
                - e. PBM metrics on solutions: scheduling, coverage, performance
        - iii. Need Ecosystem
            - 1. Affected parties
                - a. Patient characteristics
                - b. Patient group advocacy
                - c. Community health impacts
            - 2. Morbidity / mortality costs
            - 3. Costs to affected parties
            - 4. Adjacent opportunities currently infeasible
            - 5. Infrastructure
            - 6. Systems in which the need currently exists / blocks some solution
                - a. Academic research models, methods, etiology debates, diagnostics development / biomarker search
                - b. Start-ups attempting to solve same or similar problem
                - c. Attempts by larger biotech/pharma to solve problem
                - d. Clinical manifestation and management of the problem
                - e. Regulatory oversight of previous solutions / precedents
                    - i. Evolution of regulatory standards for mgmt. of solution precedents
                - f. BRICS and developing markets perspective
    - b. Stakeholder Perspectives on Need, for each: motivations, fears, profits, losses, QALY calculations, cost-benefit considerations
        - i. Patients and families
        - ii. Doctors and clinical staff
        - iii. Insurers and pharmacy benefit managers
        - iv. Venture capitalists during solution precedents
        - v. Founders involved in previous attempts to solve
        - vi. Patient advocacy groups involved in research, lobbying, or clinical education
        - vii. Clinical educators
        - viii. Diagnostic test makers and lab types
        - ix. Biotech / pharma companies
        - x. FDA / EMA
        - xi. Other countries' regulatory bodies / health systems
    - c. Need Precedents
        - i. Previous models of need – how was it recognized by:
            - 1. Clinicians
            - 2. Advocacy groups
            - 3. Scientists
            - 4. Pharma
            - 5. FDA, CDC
            - 6. Epidemiological trends
            - 7. Environmental risk factors
            - 8. Genetic risk factors
            - 9. Subpopulations where need is particularly prevalent
        - ii. Treatment advancement precedents in field of need
        - iii. Key scientific advancements in understanding / articulation / mechanism of need
        - iv. Technological progress realized in previous evolution of need recognition or treatment options / efficacy
        - v. Major revisions to diagnostic criteria
    - d. Critical Gaps in Progress on Need
        - i. Etiological unknowns
        - ii. Druggability
        - iii. Technological development
        - iv. Clinical recognition / capacity
        - v. Commercialization barriers (mfg, capital, IP)
        - vi. Why regulatory bodies have rejected or approved previous solutions
    - e. Need Ecosystem
        - i. Incentives, authorities, IP creation / licensure / transfer, KOL bodies (e.g., AACR) for and between each of the following:
            - 1. Clinicians
            - 2. Advocacy groups
            - 3. Scientists
            - 4. Pharma
            - 5. FDA, CDC
            - 6. Epidemiological trends
            - 7. Environmental risk factors
            - 8. Genetic risk factors
        - ii. Risks to and opportunities for each from a new standard / solid progress (e.g., your solution, those of competitors) in etiological understanding, treatment possibility, new infrastructure needs and capacities, diagnostic ability, or cost / side effect differentiator
        - iii. Strategic goals / institutional mandates of each
        - iv. Articulation of the kind of leverage each of the above tends to be pliable to (e.g., what things cause them to move resources or collaborate?)
    - f. Biological Complexity
        - i. GO and PPI networks involved—take with a grain of salt
        - ii. Current scientific, clinical, and insurer models for accepted disease etiology @ symptomatic, molecular, diagnostic, prognostic, and treatment effects / side effect risk factors
        - iii. Alternative hypotheses for disease etiology at genetic, molecular, cellular, or tissue systems levels
        - iv. Articulate what kinds of left-field biological disruptors of the current models could be possible
        - v. Current literature of patient heterogeneity and genetic risk variants
        - vi. Common comorbidities for target disease / condition
        - vii. Variance in prognostic outlook and significant prognostic signals / efforts to find such prognostic signatures
        - viii. Involvement of the immune system
    - g. Economics of Need
        - i. Patient costs
        - ii. Insurer costs
        - iii. Medical costs (how many specialists involved)
        - iv. Typical costs for precedents / prior solutions
        - v. Epidemiological impact
- 2. Solution Specification
    - a. Describe the current solution(s) to the problem @ 5 levels of understanding: grandma, undergrad in field, graduate student in field, professor in field, industry vet in field
    - b. Imagine and articulate the ideal, non-resource-constrained solution to the need
        - i. What would it consist of? Drugs, biomarkers, assays, production techniques, cell types, biopsies, co-treatments?
        - ii. How would it work?
        - iii. How would it be used?
        - iv. Which patients would it work for and how would they be identified or treated in the clinic?
        - v. How would it impact patients' lives?
        - vi. How would it impact doctors and clinical staff?
        - vii. How would it be made?
        - viii. How would it impact insurers or pharmacy benefit managers?
        - ix. What would regulators think about it? What aspects would they be most and least worried about?
        - x. How would potential competitors in pharma/biotech think of it?
        - xi. What additional benefits would the solution give?
    - c. Describe the difference between Sections A and B
        - i. Barriers in biological understanding
        - ii. Barriers in technological capability
        - iii. Lack of specific datasets, methods, tests
    - d. Work backwards to break section C into key changes needed to realize section A with key proofs for each, including replication across models with appropriate statistical power and analysis methods
        - i. Disease biology
        - ii. Diagnostic tools, methods, standards
        - iii. Technological breakthroughs: chemistry, biologics, cell therapy, gene editing, allogeneic sources, stem cell bio, delivery, sequencing, molecular probes, biologics mfg. etc
        - iv. Clinical practice
        - v. Regulatory oversight / new regulatory ground
    - e. Current Status – update as work progresses
        - i. Preliminary data
            - 1. Put data together in a deck and update it as new data emerges
                - a. Hypothesis → methods → results → interpretation
                    - i. Include risks retired → alternative interpretations of data → new risks introduced
            - 2. How well current data accords with previous literature
            - 3. Internal hypothesis model of system and treatment effect
            - 4. Key risks retired: mechanistic, human sample, diverse human samples, immunologically-complete animal model, dose-exposure relationship, toxicology, PKPD, off-target effects
            - 5. Narrative arc of data: significance, innovation, overarching hypothesis, key findings, their meaning, and critical next questions
        - ii. Ongoing work
            - 1. Key proofs being obtained
            - 2. Work sites, capacities thereof
            - 3. Collaborators
        - iii. Intellectual property status
            - 1. Inventors and affiliations + motivations if necessary
            - 2. Current IP status: provisional, filed, perfected
            - 3. List of prior disclosures, even in confidential environment
            - 4. Freedom to operate analysis
            - 5. Patentability analysis
        - iv. Stakeholder engagement
            - 1. Key questions, findings, and perspectives from discussions / interviews with:
                - a. Patients / patient advocates
                - b. Doctors in the field
                - c. KOL scientists
                - d. Insurers (when available)
                - e. Regulators (when available)
                    - i. Seek perspectives of colleagues working on similar projects in EMA, Japan, BRICS
        - v. Articulate difference between E and B to generate milestones and events that help the company formulate and communicate strategy
            - 1. Organize by which differences most likely to be altered by technical progress
            - 2. Organize potential generations of the solution to be built
                - a. Minimal needed features for launch (clinical trials)
                    - i. How it needs to work
                        - 1. Define critical quality attributes
                        - 2. Define critical performance characteristics
                        - 3. Potential side effects by severity, including etiology, detection method, and risk to patients
                    - ii. How it needs to be made / delivered
                        - 1. Supply chain and mfg. / delivery environment
                - b. Value-adding parameters
                    - i. What those parameters consist of
                        - 1. Clinical trials: biomarkers, companion diagnostics, non-invasive data sources
                        - 2. Additional disease indications
                        - 3. Potential combination treatments
                        - 4. Infrastructure investment pay-offs
                        - 5. Datasets acquired and interpreted
                    - ii. Who would find each parameter more valuable: partners, regulators, others
    - f. Key Milestones
        - i. Data needed to file pivotal IP
        - ii. Data needed for seminal publications
        - iii. Data needed for strategic partnerships
        - iv. Data needed to file IND
        - v. Data needed to begin Phase 0/1
        - vi. Data needed for market approval
        - vii. Data / success needed for IPO / M&A
    - g. TPP
        - i. Indications and usage (clinical target, molecular target, expected effects)
        - ii. Dosage and administration (PKPD profile needed, if estimable)
        - iii. Dosage forms and strengths ( + co-treatments)
        - iv. Contraindications (anticipated or measured; comorbidity risk factors)
        - v. Warnings and precautions (potential negative outcomes / interactions)
        - vi. Adverse reactions (anticipated range of side effects based on drug mechanism and expression of target in other cells / tissues)
        - vii. Drug interactions (hard to predict de novo)
        - viii. Use in specific populations (target population, additional patients that could benefit)
        - ix. Drug abuse and dependence
        - x. Overdosage (worst case overtreatment effects)
        - xi. Description
            - 1. Composition of matter
            - 2. Indicated use
            - 3. Clinical practice
            - 4. Formulation
            - 5. Adverse event / side effects monitoring
        - xii. Clinical pharmacology (PKPD, biodistribution, dose-exposure, excretion)
        - xiii. Nonclinical toxicology
- 3. Translational Plan
    - a. Preclinical mechanistic studies
        - i. List of disease models, features of human disease it recapitulates, idiosyncratic risks it introduces for each
            - 1. Cell lines / iPSCs
            - 2. Organoids
            - 3. Primary explants
            - 4. Primary cell organoids
            - 5. GEMMs
            - 6. Xenotransplantation
            - 7. Chemical or genetic exposure
        - ii. Endpoints necessary to show MOA
            - 1. On-target efficacy
            - 2. Off-target effects
            - 3. Side effects
            - 4. Optimization opportunities
        - iii. Correlation ain't enough, knock something out!
        - iv. Necessity and sufficiency of molecular targets
        - v. Dose-exposure relationship
    - b. IND prep
        - i. Disease models and effect endpoints
        - ii. Safety profile: ADMETox
        - iii. PKPD
        - iv. Drug metabolism
        - v. cGMP mfg pilot
        - vi. Biomarker / companion diagnostic development
            - 1. Determine how biomarkers / dx to be used and whether / when investigational device exemption needs to be applied for
    - c. Regulatory engagement
        - i. Prev regulatory standards for comparable products
        - ii. Relevant industry guidances and press releases
        - iii. Pre-IND meeting planning
        - iv. Protocol development / change / update procedure
        - v. IRB oversight and composition planning
    - d. Clinical trial planning
        - i. Site selection
        - ii. Protocol development
            - 1. Inclusion criteria
            - 2. Exclusion criteria
        - iii. Protocol management / implementation
        - iv. Chain of custody for samples
        - v. Endpoints to be run on samples
        - vi. Data & access / encryption mgmt. strategy
    - e. Phase 0 or diagnostic sensitivity
    - f. Phase 1 or diagnostic specificity
    - g. Phase 2
    - h. Phase 3
    - i. Additional indications
    - j. Full TPP, update at each stage
- 4. Business Plan
    - a. Value Model
        - i. Significance statement
        - ii. Innovation statement
        - iii. Overarching hypothesis: if successful, then ________
        - iv. Value to patients
        - v. Value to doctors
        - vi. Value to clinical practice
        - vii. Value to pharmacy benefit managers / insurers
        - viii. Regulatory or professional body recognition of problem urgency, scope, impact, etc
        - ix. Market value
            - 1. Present market for drugs used currently
            - 2. Market segmentation
            - 3. Parameter space of all possible solutions to the need
            - 4. Competitor pipelines w/ analysis
            - 5. Future market trends
        - x. Market differentiation
            - 1. Features / fronts by which competition plays out
            - 2. Infrastructural features that enable market access
            - 3. Proactive regulatory engagement
            - 4. Treatment delivery / deployment
            - 5. Partnering strategy—hospitals, patient advocacy groups, collaborators, academic centers, regulatory bodies, etc.
        - xi. Intellectual property
            - 1. Freedom to operate analysis
            - 2. Patentability analysis
            - 3. Licensing considerations
    - b. Project Model
    - c. Need Model
        - i. Etiology Model: molecular, cell, tissue, organ, host, patient-to-patient variability
        - ii. Intervention Context Model (Clinical Perspectives)
            - 1. Diagnostic criteria and common misdiagnoses
            - 2. First-line treatments and efficacy monitoring
            - 3. Second-line treatments
            - 4. Monitoring of disease progression
            - 5. Clinical setting
            - 6. Healthcare professional education, training, experience
            - 7. Detection of clinical complications of treatment
        - iii. Intervention Model Mechanism of Action
            - 1. Drug MOA by cell type, genetic background, disease stage – can be hypothetical but should include what kinds of data can confirm or reject when possible
            - 2. On-target activity and effects
            - 3. Off-target activity and effects (may be putative)
            - 4. How treatment alters disease etiology, progression, co-morbidity
            - 5. Long-term usage
        - iv. Addressable Population Model
            - 1. Epidemiological trends by geographic area and environmental exposure
            - 2. Genetic risk variants
            - 3. Environmental risk variations
            - 4. Patient heterogeneity
                - a. Symptomology
                - b. Demographic
                - c. Comorbidity background
            - 5. Accessibility of health care
        - v. Alternative models and what new scientific data would validate them
    - d. Customer Model
        - i. Patient
        - ii. Doctor
        - iii. Insurer
        - iv. PBM
        - v. Pharma
        - vi. FDA / EMA
        - vii. Patient advocate groups
    - e. Competitor Model
        - i. Competitor landscape
            - 1. Pipelines
            - 2. Partnerships
            - 3. Star personnel & histories
            - 4. IP opportunities
            - 5. Funding and development stage
        - ii. Strategic vulnerabilities in ecosystem incumbents
            - 1. Pipeline failures
            - 2. M&A in the same area that didn't work out
            - 3. Areas that they have a lot of marketing, distribution, or manufacturing investments concentrated
    - f. Regulatory Model
        - i. Precedents for regulatory engagement for similar projects
        - ii. Relevant regulatory guidances and interactions
        - iii. List of anticipated regulatory concerns—update after meetings
    - g. Drivers & Sinks
        - i. Value Drivers
        - ii. Need Drivers
        - iii. Progress/Success Drivers
        - iv. Risk Drivers
        - v. Competition Drivers
    - h. Present Value Justification
        - i. Data
        - ii. IP
        - iii. rNPV for products based on market trends
        - iv. Partnership goals
        - v. Pipeline
    - i. Future Value Justification
        - i. Clinical data
        - ii. Pipeline development
        - iii. Scientific / medical leadership
        - iv. Partnership strategy
        - v. Exit options
    - j. Risk Management Strategy
        - i. How could your solution fail?
        - ii. What can you do to detect early signs of a failure point?
        - iii. What's your plan for fixing them?
        - iv. Which risks get retired at which milestones and why
        - v. Which aspects of the solution, opportunity, or translation process are concretely-established medical science and which are less well-settled and subject to potential changes?
- 5. Emergent Opportunities (things that become possible as 1-4 progress)
    - a. Synergies / Cantilevers – where meeting a given milestone significantly lowers the cost to entry of an additional value-creating opportunity
    - b. Field Futurism – where the underlying scientific frontiers are headed and how to make win-wins out of project planning for current priorities and being able to realize emerging opportunities later (e.g., building specialized infrastructure that can find broader application after a given tech bottleneck is surpassed)
    - c. Leftfield Biological Realities
    - d. Collaborations and Partnerships
    - e. Patient Advocacy
    - f. Platformization
    - g. Swarm Mode
    - h. Human Benefits!
        - i. Mortality reduced
        - ii. Lost economic value restored
        - iii. Quality of life improvements
        - iv. What happens to health when your patents expire or your tech becomes cheap and easy?
        - v. Plan to actually interact with the human beings whose lives your efforts will touch—do not stay away from clinics, patient groups, or families
    - i. Application to emerging markets
    - j. Care Support
        - i. Biomarkers for diagnosis
        - ii. Biomarkers for treatment monitoring and follow-up
        - iii. Digital infrastructure
        - iv. Clinical IT integration and extension
        - v. Liability reduction (e.g., gene therapy monitoring for pay-for-performance models)